Drug intelligence / Profile preview

synbiotics mixture I

Development stage: Preclinical
Lead developer: Danone
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Synbiotics mixture I is a specific formulation of synbiotics, a combination of probiotics and prebiotics, designed to be added to infant formula. It is being investigated for its effect on the gut microbiota composition in healthy infants, with the aim of increasing the proportion of beneficial bacteria. This mixture is developed by Danone Asia Pacific Holdings Pte, Ltd. and is considered a dietary supplement and nutraceutical due to its role in promoting gut health.

Beyond the preview

Go deeper on synbiotics mixture I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on synbiotics mixture I.

Explore the full profile